当前相当比例血管内主动脉瘤修复实践未达到血管外科学会临床实践指南推荐的腹主动脉瘤直径治疗阈值:VQI登记分析
分析VQI登记2015-2019年25112例择期EVAR,38.5%未达SVS直径指南(男≥5.5cm、女≥5.0cm),中心间合规率21%-95%、术者间0-100%,82%术者超20%修复不合规,高生理风险不合规者1年生存较合规低中风险者差。
要点
- 38.5%择期EVAR未达SVS直径指南阈值,仅61.5%合规。
- 中心合规率21%-95%,术者0-100%,82%术者超20%修复不合规。
- 不合规者中22.4%为高生理风险,其1年生存低于合规低中风险者。
核心结论
- 当前美国EVAR实践相当比例未遵守SVS直径指南,中心与术者间差异巨大。
- 不合规修复中22.4%为高生理风险,患者选择似不理想。
- 作者认为限制偏离推荐尺寸阈值指南的努力可能改善腹主动脉瘤诊疗。
研究设计与样本
- 分析SVS血管质量倡议(VQI)EVAR登记2015-2019年所有择期修复(n=25,112),纳入肾下腹主动脉瘤患者。
- 采用经验证logistic回归模型进行风险调整,按预测1年死亡风险三分位分层比较。
主要发现
- 非直径合规EVAR占38.5%(n=9675),直径合规占61.5%(n=15,437)。
- 按VQI参与中心分层合规率范围21%-95%(中位数61%,P<.001),按术者分层范围0-100%(中位数63%,P<.0001)。
- 82%的VQI术者(852/1048)超过20%的修复不合规。
- 不合规患者中22.4%(n=2171)经SVS-VQI 1年死亡计算器判定为高生理风险。
- 高生理风险接受不合规EVAR者1年生存92±2%,低于合规低中风险者的97±1%(log-rank P<.0001)。
关键数值与推荐
- SVS临床实践指南直径阈值:男性≥5.5cm,女性≥5.0cm。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is mounting controversy surrounding the appropriate use of endovascular aortic aneurysm repair (EVAR) in contemporary practice. Persistent debate hinges on durability, cost, and survival. Accordingly, guidelines have attempted to clarify appropriate EVAR indications. The purpose of this analysis was to examine trends in EVAR practice throughout the United States and measure compliance with Society for Vascular Surgery (SVS) clinical practice diameter guidelines (CPGs). METHODS: We analyzed all elective repairs in the SVS Vascular Quality Initiative (VQI) EVAR registry from 2015 to 2019 (n = 25,112) and included patients with aneurysms confined to the infrarenal abdominal aorta. Center and surgeon variation with CPG diameter compliance was examined. Using a previously validated logistic regression model for risk adjustment, patients were stratified into predicted 1-year mortality risk tertiles and comparisons were made between patients meeting diameter guidelines (men ≥5.5;women ≥5.0 cm) and those who did not. RESULTS: Non-diameter-compliant EVAR occurred in 38.5% (n = 9675; diameter compliant, 61.5% [n = 15,437]). There was significant variation in CPG diameter compliance when stratified by VQI participating centers (range, 21%-95%; median, 61%; P < .001). This observation was amplified when categorized at the surgeon level (range, 0-100%; median, 63%; P < .0001). Notably, 82% of VQI surgeons (n = 852 of 1048) were non-diameter-compliant in more than 20% of their repairs. Moreover, among the 38.5% of patients failing to meet CPG diameter thresholds, 22.4% (n = 2171) were at high physiologic risk as determined by the validated SVS-VQI 1-year mortality calculator. Notably, the 1-year survival for the high-physiologic risk patients receiving non-guideline-compliant EVAR was worse compared with low- to intermediate-risk patients who were treated within recommended CPGs (92 ± 2% vs 97 ± 1%; log-rank P < .0001). CONCLUSIONS: A significant percentage of current US EVAR practice fails to adhere to the SVS diameter guidelines, as highlighted by the tremendous variation among VQI centers and surgeons. Furthermore, as noted by the 22% of patients undergoing noncompliant repair deemed to be at high physiologic risk, patient selection for EVAR seems to be suboptimal. Surprisingly, these findings are observed among the majority of VQI surgeons performing EVAR. In light of issues surrounding durability and cost, efforts to constrain observed deviation from recommended therapeutic size threshold guidelines would likely serve to improve abdominal aortic aneurysm care throughout the United States.
引用
- Scali ST, Suckow BD, Goodney PP, et al. A significant proportion of current endovascular aortic aneurysm repair practice fails to meet Society for Vascular Surgery clinical practice guideline recommended abdominal aortic aneurysm diameter treatment thresholds in the Vascular Quality Initiative. J Vasc Surg. 2022. PMID: 35090992. doi:10.1016/j.jvs.2021.08.109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。